MAPT and Alzheimer disease: Trimethylamine N-oxide (TMAO)—derived from gut microbial metabolism of dietary choline—disrupts blood–brain barrier tight junctions, promotes tau hyperphosphorylation, and activates the NLRP3 inflammasome, correlating with elevated mild cognitive impairment (MCI)-to-AD conversion risk [48,49].